Kyntra Bio
KYNB
54 hedge funds and large institutions have $10.2M invested in Kyntra Bio in 2025 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 14 increasing their positions, 16 reducing their positions, and 19 closing their positions.
320% more call options, than puts
Call options by funds: $193K | Put options by funds: $46K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.13% less ownership
Funds ownership: 1.44% → 1.31% (-0.13%)
13% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 16
21% less funds holding
Funds holding: 68 → 54 (-14)
47% less capital invested
Capital invested by funds: $19.2M → $10.2M (-$8.98M)
74% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$815K |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$454K |
| 3 |
HighTower Advisors
Chicago,
Illinois
|
+$145K |
| 4 |
Group One Trading
Chicago,
Illinois
|
+$40.6K |
| 5 |
Morgan Stanley
New York
|
+$28.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
-$1.13M |
| 2 |
Renaissance Technologies
New York
|
-$421K |
| 3 |
Primecap Management
Pasadena,
California
|
-$420K |
| 4 |
Mackenzie Financial
Toronto Ontario,
Ontario, Canada
|
-$290K |
| 5 |
Squarepoint
New York
|
-$205K |
KYNB Hedge Fund Activity: Q1 2025 in Review
54 of the 7,469 institutional investors tracked by Wall St. Rank reported a position in Kyntra Bio (KYNB) for Q1 2025, worth a combined $10.2M — down 47% from $19.2M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of KYNB and 5 opened new positions — a net loss of 14 holders — while 16 trimmed existing stakes and 14 added.
The largest buyer was Armistice Capital, adding an estimated $815K. The largest seller was 683 Capital Management, exiting entirely with an estimated $1.13M sold.
- 54 institutional investors held Kyntra Bio (KYNB) as of Q1 2025, down from 68 in Q4 2024.
- Funds reported $10.2M of Kyntra Bio stock for Q1 2025, down 47% quarter-over-quarter.
- 5 funds opened new Kyntra Bio positions in Q1 2025 and 19 closed out, a net change of -14 holders.
- The largest Kyntra Bio buyer in Q1 2025 was Armistice Capital, an estimated $815K added.
- The largest Kyntra Bio seller in Q1 2025 was 683 Capital Management, an estimated $1.13M sold.
Based on aggregated 13F filings for Q1 2025.